KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Castle Biosciences (CSTL) Non-Current Receivables (2018 - 2025)

Historic Non-Current Receivables for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $2.0 million.

  • Castle Biosciences' Non-Current Receivables rose 8535.26% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 8535.26%. This contributed to the annual value of $918000.0 for FY2024, which is 2292.19% down from last year.
  • Castle Biosciences' Non-Current Receivables amounted to $2.0 million in Q3 2025, which was up 8535.26% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Non-Current Receivables peaked at $2.0 million during Q3 2025, and registered a low of $918000.0 during Q4 2024.
  • For the 5-year period, Castle Biosciences' Non-Current Receivables averaged around $1.2 million, with its median value being $1.2 million (2023).
  • Its Non-Current Receivables has fluctuated over the past 5 years, first skyrocketed by 10138.04% in 2021, then tumbled by 2292.19% in 2024.
  • Over the past 5 years, Castle Biosciences' Non-Current Receivables (Quarter) stood at $1.3 million in 2021, then fell by 16.9% to $1.1 million in 2022, then grew by 9.57% to $1.2 million in 2023, then dropped by 22.92% to $918000.0 in 2024, then surged by 123.31% to $2.0 million in 2025.
  • Its Non-Current Receivables stands at $2.0 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.0 million for Q1 2025.